本帖最后由 老马 于 2012-1-13 21:20 编辑
. V: z) }, A2 m1 J: u- X
4 K1 i2 x; B3 F- \9 v( y爱必妥和阿瓦斯丁的比较' c& p. U1 _0 z
; d9 J3 X9 c7 O d- rhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
2 A0 L: w/ K* k& C' O* ?
+ y1 k2 r+ z1 R, B- S* f {
! c! K$ l7 N# }2 z, V Z; x; T
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/4 l \) _; N& k! J+ J3 D
==================================================) X# l9 ]/ p8 m# h7 B& g
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)- v* p; ~2 `8 G+ }6 Y5 j; n K
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.- N8 J2 t$ W* U! |' c3 R% q! Z
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.$ |1 C" C; f: g5 r
|
11011102001537 )
显身卡
+ h- n4 K7 w0 Y, Y9 K; M- Y
